Table 3. Rate of overall survival NADCs by patients' characteristics.
| Variables | Categories | NADCs (n = 431) | P-value | LIVER CA (n = 69) | P-value | LUNG CA (n = 35) | P-value | BREAST CA (n = 30) | P-value | HODGKIN LYMPHOMA (n = 61) | P-value | |||||||||
| 1y | 5y | 10y | 1y | 5y | 10y | 6month | 1y | 3y | 5y | 10y | 1y | 5y | 10y | |||||||
| Total | 76.1±2.1 | 59.2±2.7 | 45.0±4.1 | 59.8±6.0 | 31.9±6.4 | - | 54.4±8.7 | 28.0±8.6 | 96.7±3.3 | 78.1±8.9 | 65.1±14.0 | 74.2±5.7 | 57.8±7.2 | 24.8±11.2 | ||||||
| Gender | 0.152 | 0.380 | NE* | 0.089 | 0.003 | |||||||||||||||
| Male | 74.7±2.4 | 56.8±3.1 | 40.9±4.8 | 56.0±6.5 | 27.4±6.8 | - | 58.3±9.3 | 32.0±9.6 | 80.0±17.9 | 53.3±24.8 | 26.7±22.6 | 77.0±5.8 | 63.0±7.5 | 27.1±12.2 | ||||||
| Female | 80.4±4.0 | 67.4±5.1 | 58.6±6.5 | 87.5±11.7 | 62.5±17.1 | - | - | - | 90.3±6.6 | 83.9±8.7 | 83.9±8.7 | 50.0±20.4 | - | - | ||||||
| Age, years | 0.331 | 0.096 | 0.094 | 0.108 | 0.045 | |||||||||||||||
| 18–34 | 82.3±6.6 | 68.4±8.4 | 62.1±9.6 | - | - | - | - | 66.7±2.7 | 33.3±2.7 | 33.3±2.7 | 83.1±11.0 | 71.2±14.5 | 71.2±14.5 | |||||||
| 35–49 | 76.2±2.7 | 58.1±3.5 | 42.4±5.3 | 67.9±6.8 | 33.2±7.5 | - | 42.8±13.2 | 14.3±9.3 | 88.2±7.9 | 80.9±10.1 | 53.9±23.0 | 68.3±7.6 | 49.5±8.6 | 9.9±9.0 | ||||||
| 50-max | 74.2±3.8 | 59.4±5.0 | 44.5±8.1 | 40.9±11.1 | 35.1±10.9 | - | 81.6±5.3 | 71.1±6.4 | - | - | - | 88.9±10.5 | 88.9±10.5 | 88.9±10.5 | ||||||
| IVDU | 0.007 | 0.753 | 0.606 | 0.292 | 0.686 | |||||||||||||||
| No | 81.7±2.5 | 63.1±3.7 | 53.5±5.4 | 60.5±13.8 | 32.3±16.7 | - | 57.9±12.2 | 30.4±13.4 | 86.5±7.3 | 80.8±8.8 | 80.8±8.8 | 78.1±7.3 | 60.2±9.8 | 60.2±9.8 | ||||||
| Yes | 68.7±3.5 | 54.1±4.0 | 37.2±5.5 | 59.6±6.7 | 31.8±6.7 | - | 50.9±12.5 | 25.5±11.0 | 100 | 66.7±2.7 | - | 70.0±8.9 | 56.1±10.2 | 18.7±11.3 | ||||||
| AIDS event | 0.008 | 0.683 | 0.074 | 0.480 | 0.021 | |||||||||||||||
| No | 78.5±2.7 | 67.4±3.3 | 48.6±6.0 | 56.8±7.9 | 40.5±8.4 | - | 56.7±10.9 | 39.2±11.4 | 92.9±6.8 | 85.1±9.7 | 63.8±19.8 | 82.2±7.3 | 74.8±9.7 | 24.9±20.6 | ||||||
| Yes | 72.8±3.4 | 48.6±4.3 | 39.7±5.4 | 64.3±9.1 | 22.7±9.3 | - | 50.3±14.4 | - | 82.5±11.3 | 68.7±15.7 | 68.7±15.7 | 65.5±8.8 | 41.3±9.7 | 20.7±11.4 | ||||||
| Coinfection | 0.146 | NE* | 0.295 | 0.850 | 0.699 | |||||||||||||||
| No | 78.1±3.1 | 62.2±4.1 | 52.1±6.1 | - | - | 63.6±11.1 | 33.9±12.6 | 83.5±10.8 | 74.3±13.0 | 74.3±13.0 | 64.5±9.1 | 59.6±9.7 | 59.6±9.7 | |||||||
| Yes | 74.5±2.9 | 56.9±3.6 | 40.6±5.2 | 59.8±6.0 | 31.9±6.4 | 42.9±13.2 | 21.4±11.0 | 92.9±6.9 | 79.6±13.6 | 39.8±28.9 | 83.3±6.8 | 59.0±9.9 | 19.7±11.8 | |||||||
| cART | 0.152 | 0.572 | NE* | NE* | 0.532 | |||||||||||||||
| No | 71.9±6.4 | 47.2±7.4 | 43.9±7.6 | 57.1±16.4 | 45.7±16.6 | - | - | - | - | - | - | 80.0±17.9 | 40.0±21.9 | - | ||||||
| Yes | 76.7±2.2 | 61.0±2.9 | 45.1±4.5 | 60.2±6.5 | 29.0±7.0 | - | 57.0±9.4 | 34.1±9.9 | 96.7±3.3 | 78.1±8.9 | 65.1±14.0 | 73.7±6.1 | 60.4±7.5 | 25.9±11.7 | ||||||
| CD4+ T-cell count, cell/mm3 | 0.014 | 0.225 | NE* | 0.270 | 0.006 | |||||||||||||||
| 200-max | 78.1±2.4 | 62.4±3.2 | 48.7±5.1 | 61.6±6.9 | 38.8±8.2 | - | 61.7±9.6 | 32.1±10.4 | 91.7±8.0 | 81.5±11.9 | 81.5±11.9 | 83.2±5.8 | 63.3±8.6 | 25.3±14.3 | ||||||
| 0–199 | 68.7±4.7 | 48.8±5.3 | 32.7±7.0 | 59.2±11.9 | 17.8±9.3 | - | - | - | 80.0±12.6 | 68.6±15.1 | 51.4±18.7 | 50.0±13.4 | 40.0±13.4 | - | ||||||
| Nadir CD4+ counts, cell/mm3 | 0.337 | 0.891 | 0.427 | 0.433 | 0.083 | |||||||||||||||
| ≥200 | 76.2±3.3 | 62.9±4.3 | 51.6±6.8 | 53.1±9.9 | 31.9±12.1 | - | 64.0±10.9 | 33.9±11.5 | 90.9±8.7 | 90.9±8.7 | 90.9±8.7 | 81.9±9.5 | 51.6±14.0 | - | ||||||
| 50–199 | 78.4±3.2 | 57.9±4.3 | 42.9±6.0 | 61.0±8.5 | 30.5±8.3 | - | 57.1±16.4 | 21.4±17.5 | 85.7±13.2 | 64.3±2.1 | 64.3±2.1 | 78.6±7.7 | 50.6±8.4 | 40.7±16.0 | ||||||
| <50 | 71.1±5.0 | 54.4±6.2 | 39.5±8.8 | 75.0±15.3 | 37.5±17.1 | - | - | - | 87.5±11.7 | 72.9±16.5 | 48.6±22.7 | 52.7±14.1 | 44.0±14.3 | - | ||||||
| HIVRNA, copies/mL | 0.110 | 0.149 | NE* | 0.668 | 0.233 | |||||||||||||||
| Undetectable | 79.8±2.9 | 60.0±4.6 | 48.5±7.6 | 69.9±7.6 | 35.9±9.9 | - | 72.3±10.6 | 47.9±13.7 | 100 | 53.3±24.8 | - | 85.0±7.9 | 67.7±13.2 | - | ||||||
| Positive | 71.7±3.2 | 55.8±3.7 | 41.7±4.9 | 49.0±9.3 | 26.4±8.4 | - | - | - | 81.7±9.6 | 81.7±9.6 | 81.7±9.6 | 68.7±7.9 | 55.1±8.8 | 22.0±12.6 | ||||||
Note: Plus minus are value standard error, P value are from long rank test. - The sample size was too small for Kaplan Meier analysis.
*NE, not evaluable.
NADCs: Non-AIDS-defining cancers, IVDU: Intravenous Drug Use, cART: combined antiretroviral therapy; CA: cancer.